Healthcare & Psychology · Real arguments from SuperDebate members below
Phase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months — a remission rate no existing treatment approaches. Psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression. For conditions that have...
Posted by jconnor
Psilocybin mushrooms, peyote, and ayahuasca each have documented histories of safe ceremonial and therapeutic use spanning millennia. The unknown-risk framing applies to rapid pharmaceutical commercialization, not to the substances themselves. Safety profiles are better understood for these...
Posted by jconnor
The FDA's 2024 rejection was based on trial-design concerns, not evidence of harm. The solution is a clear licensing pathway with rigorous therapist certification requirements and supervised administration protocols — not continued prohibition of the most promising psychiatric drug class in 50...
Posted by jconnor
The most rigorous MDMA trial the FDA reviewed in 2024 failed to beat placebo in one of two Phase 3 studies. The blinding problem is severe: participants almost always know they took the drug, making expectancy effects inseparable from pharmacological ones. The effect size may be mostly placebo...
Posted by jconnor
Psychedelics carry real risks: triggering latent psychosis, cardiac events with MDMA, and serious ethical violations in therapeutic contexts. Three therapists in MAPS's own trials were found to have sexually abused patients during or after sessions. The vulnerability of people in altered states...
Posted by jconnor
The set, setting, and therapeutic relationship appear to drive most of the effect. The commercialization model — brief drug administration with minimal therapy — strips out what actually works while profiting from the brand. That approach serves investors at the expense of patient safety and...
Posted by jconnor
Debate this exact resolution against the AI coach and get scored feedback.
Practice with the coachPhase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months — a remission rate no existing treatment approaches. Psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression. For conditions that have... (Argued by jconnor on SuperDebate.)
The most rigorous MDMA trial the FDA reviewed in 2024 failed to beat placebo in one of two Phase 3 studies. The blinding problem is severe: participants almost always know they took the drug, making expectancy effects inseparable from pharmacological ones. The effect size may be mostly placebo... (Argued by jconnor on SuperDebate.)
A live debate on this topic is on the SuperDebate schedule. Anyone can watch, and members can put themselves forward to argue a side.
On SuperDebate. Post a written argument on the topic page, rehearse the resolution against the AI debate coach, or take it to a live debate night at a club near you. Joining is free.
